{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106243","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.564382+00:00","generated_at":"2026-05-17T15:31:00.268627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027","bullets":["Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.","Net loss $54.7M vs $35.0M Q2 2024; R&D spend $48.0M (+50% YoY) on Phase 3 startup.","4FRONT-1 wet AMD Phase 3 topline data accelerated to H1 2027; 4FRONT-2 initiated ahead of schedule.","DME SPECTRA 60-wk: Phase 3 dose 78% fewer injections vs on-label aflibercept; FDA/EMA align on single-study approval.","RMAT designation for 4D-150 in DME; 4D-710 cystic fibrosis cohort enrollment complete, data Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106243","json":"https://secwatch.observer/filing/0000950170-25-106243.json","markdown":"https://secwatch.observer/filing/0000950170-25-106243.md","text":"https://secwatch.observer/filing/0000950170-25-106243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/0000950170-25-106243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:31:00.268627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}